Oppenheimer & Co. Inc. Cuts Holdings in Illumina, Inc. (NASDAQ:ILMN)

Oppenheimer & Co. Inc. decreased its position in Illumina, Inc. (NASDAQ:ILMN) by 0.5% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 40,668 shares of the life sciences company’s stock after selling 219 shares during the period. Oppenheimer & Co. Inc.’s holdings in Illumina were worth $5,434,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Versant Capital Management Inc increased its holdings in Illumina by 153.7% in the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock valued at $32,000 after buying an additional 146 shares in the last quarter. Golden State Wealth Management LLC purchased a new position in Illumina in the fourth quarter valued at $32,000. TD Private Client Wealth LLC increased its holdings in Illumina by 58.5% in the third quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock valued at $50,000 after buying an additional 141 shares in the last quarter. V Square Quantitative Management LLC increased its holdings in Illumina by 50.6% in the fourth quarter. V Square Quantitative Management LLC now owns 393 shares of the life sciences company’s stock valued at $52,000 after buying an additional 132 shares in the last quarter. Finally, First Horizon Advisors Inc. increased its holdings in Illumina by 73.5% in the fourth quarter. First Horizon Advisors Inc. now owns 439 shares of the life sciences company’s stock valued at $59,000 after buying an additional 186 shares in the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Stock Performance

NASDAQ:ILMN opened at $88.74 on Friday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42. The firm has a market capitalization of $14.06 billion, a price-to-earnings ratio of -11.55, a PEG ratio of 1.60 and a beta of 1.10. The company’s 50-day moving average is $123.38 and its two-hundred day moving average is $132.96. Illumina, Inc. has a 1-year low of $87.50 and a 1-year high of $156.66.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. Analysts forecast that Illumina, Inc. will post 4.51 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the stock. Morgan Stanley cut their target price on shares of Illumina from $150.00 to $136.00 and set an “equal weight” rating for the company in a research note on Tuesday, February 11th. Citigroup cut shares of Illumina from a “buy” rating to a “neutral” rating and cut their target price for the stock from $190.00 to $165.00 in a research note on Wednesday, December 11th. Royal Bank of Canada cut their target price on shares of Illumina from $250.00 to $247.00 and set an “outperform” rating for the company in a research note on Friday, February 7th. Barclays cut shares of Illumina from an “equal weight” rating to an “underweight” rating and cut their target price for the stock from $130.00 to $100.00 in a research note on Monday, February 10th. Finally, UBS Group boosted their target price on shares of Illumina from $133.00 to $145.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating, ten have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $155.45.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.